Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Vaccine

Chikungunya vaccine (live attenuated)

Brand names: Ixchiq

This is a live attenuated vaccine used to provide active immunisation against chikungunya virus disease in eligible adults, typically travellers to endemic areas.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It contains a live attenuated chikungunya virus strain that stimulates the immune system to produce protective neutralising antibodies against the virus.

Prescribing in practice

  • As a live vaccine it is contraindicated in significantly immunocompromised individuals and requires caution in pregnancy, with use guided by MHRA and current immunisation advice.
  • Following MHRA and UK safety review, use in older adults has been approached cautiously pending evaluation of serious adverse events in that group.
  • Assess suitability against the current chikungunya vaccination recommendations and the individual's travel risk before administering.

Monitoring

Observe the patient after vaccination for immediate hypersensitivity and counsel on delayed reactions, reporting suspected adverse effects via the Yellow Card scheme.

Counselling the patient

  • This vaccine helps protect against chikungunya, a mosquito-borne viral illness.
  • Continue mosquito-bite precautions when travelling, as no vaccine is fully protective.
  • Report any severe or persistent reaction after vaccination.

Evidence & guidelines

Use is governed by MHRA licensing and current UK travel immunisation guidance, which is periodically updated as safety data accumulate.

Reference: UK Green Book; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Drugs
Pathways